Analysts give the thumbs up to Bristol-Myers Squibb's (BMY -0.25%) and AstraZeneca's (AZN -1.2%) purchase of Amylin (AMLN). "The acquisition is a good strategic fit...with a sound financial basis and tangible economic benefits," says Deutsche Bank. UBS, Wells Fargo and Leerink Swann are also positive.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs